Opendata, web and dolomites

RAPID

The first effective remedy for acute pancreatitis disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RAPID project word cloud

Explore the words cloud of the RAPID project. It provides you a very rough idea of what is the project "RAPID" about.

hospitalizations    store    muscular    pave    pharmacological    providers    ions    orientale    overload    rare    piemonte    therapies    reinvested    gastroenterology    visits    million    discharge    cellular    phases    small    operated    39    dossier    disease    position    diagnosis    validation    solutions    complete    endoscopic    accelerated    market    frame    aggregate    intensive    trials    burden    plan    innovation    company    ready    trigger    care    validate    proved    admitted    breakthrough    globally    candidate    clinical    paths    calcium    regulatory    yearly    data    room    ema    preclinically    prepare    healthcare    myopathy    services    utmost    drug    finance    hyper    pharma    fda    prior    last    ap    initiation    generating    advantage    people    pancreatitis    national    emergency    dystrophy    entry    off    capacity    orphan    time    patients    undergo    revenues    activation    university    surgical    molecules    cluster    preclinical    patented    tech    indications    health    spin    2024    modulate    optimal    designation    duchenne    acute    frequent    diseases    chemicare    license    costing    therapeutic    tubular    rapid    solution   

Project "RAPID" data sheet

The following table provides information about the project.

Coordinator
CHEMICARE SARL 

Organization address
address: VIA AMICO CANOBIO 4/6
city: NOVARA
postcode: 28100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://www.chemicare.it/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHEMICARE SARL IT (NOVARA) coordinator 50˙000.00

Map

 Project objective

ChemICare is a high-tech spin-off of the University of Piemonte Orientale and has patented and preclinically developed small molecules that are unique in their capacity to modulate calcium ions uptake in cellular processes. Calcium overload associated with Store-Operated Calcium Entry hyper-activation has been proved to be to be the key trigger in a cluster of diseases, including Acute Pancreatitis, which affects over 10 million people globally and is the most common gastroenterology discharge diagnosis in Europe and the US. AP is associated with significant disease burden, emergency room visits, frequent hospitalizations, and patients often undergo endoscopic and surgical procedures and are admitted to intensive care, costing more than 20 B€ yearly to National Healthcare Services. Preclinical data obtained so far demonstrate that drug candidate 39 represents a breakthrough innovation in the field of pharmacological therapies for AP. We are now in the process of generating the last data to complete the preclinical regulatory dossier, which will pave the way for the Phase I and II clinical trials which will lead to an out-license agreement to a large pharma company prior to the initiation of Phase III. The revenues will therefore be reinvested to finance development of the same technology for other therapeutic indications associated with calcium overload (e.g. Duchenne Muscular Dystrophy and Tubular Aggregate Myopathy). This Phase 1 is of utmost importance to validate the market position of ChemICare molecules, apply for orphan designation, and plan the preclinical study necessary to prepare the clinical validation Phases in the frame of the Phase 2. Our goal is to have a solution ready for the market by 2024, which will be cost-effective for health providers and deliver optimal care to patients with AP. Such rapid time-to-market is possible because both EMA and FDA have accelerated paths for rare disease solutions that we will take advantage of.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAPID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

ELDICO ED (2019)

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Read More